More conflict on tap in Figueroa Mountain’s bankruptcy
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Cure Pharmaceutical navigates CBD acquisition, licensing dispute
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Inogen’s new CEO looks to the future
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →GeoLinks keeps up growth pace, may open satellite offices soon
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →How to borrow $4 billion: With financing secure, path is nearly clear for Teledyne/Flir deal
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Revenues and losses both grew at Cure in 2020
Cure Pharmaceutical, an Oxnard company with a CBD products subsidiary, reported steep revenue growth but rising net losses in the fourth quarter and full year of 2020. In an annual statement released April 1, Cure reported revenue of $2.1 million in the final quarter of 2020, up 229% from the same quarter a year before. Read More →
Read More →Amgen announces $721M acquisition
Amgen reported its second major acquisition of the month, as the Thousand Oaks-based firm announced March 30 that it will acquire Rodeo Therapeutics Corporation, a privately held biotech company based in Seattle. The deal is worth more than $700 million, $55 million of which will be paid upfront, with up to $666 million more in Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
